Immunocore Holdings Ltd
$ 33.98
-0.06%
10 Aug - close price
- Market Cap 1,729,430,000 USD
- Current Price $ 33.98
- High / Low $ 34.28 / 33.52
- Stock P/E N/A
- Book Value 7.75
- EPS -0.36
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.04 %
- 52 Week High 40.71
- 52 Week Low 27.55
About
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Analyst Target Price
$63.67
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-06 | 2026-02-25 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-28 | 2023-11-07 |
| Reported EPS | -0.02 | 0.25 | -0.6 | -0.0035 | -0.2 | 0.1 | -0.3714 | 0.17 | -0.23 | -0.49 | -32.22 | 0.05 |
| Estimated EPS | -0.01 | -0.26 | -0.197 | -0.24 | -0.21 | -0.4 | -0.1594 | -0.34 | -0.52 | -0.38 | -21.74 | -0.36 |
| Surprise | -0.01 | 0.51 | -0.403 | 0.2365 | 0.01 | 0.5 | -0.212 | 0.51 | 0.29 | -0.11 | -10.48 | 0.41 |
| Surprise Percentage | -100% | 196.1538% | -204.5685% | 98.5417% | 4.7619% | 125% | -132.9987% | 150% | 55.7692% | -28.9474% | -48.2061% | 113.8889% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMCR
2026-08-10 16:10:02
Immunocore Holdings (IMCR) presents a trade-off between its growing Kimmtrak product revenue and a premium valuation. While Kimmtrak's sales are strong and late-stage studies could expand its market, the company's reliance on a single product and higher-than-average valuation metrics pose risks. Analysts currently recommend a "Hold" stance, suggesting patience due to these factors.
2026-08-08 21:10:02
Immunocore Holdings plc (IMCR) stock information is provided, including its current price of $34.56, up 1.71% in after-hours trading. The company, headquartered in the UK, focuses on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune conditions, with its lead product KIMMTRAK approved for uveal melanoma. The article also details IMCR's financial overview, clinical pipeline, performance metrics, and analyst insights.
2026-08-07 17:39:49
Immunocore (IMCR) reported a Q2 2026 loss of 2 cents per share, wider than analyst estimates, despite revenues of $115.9 million, which beat expectations and increased 18.3% year-over-year. The revenue growth was primarily driven by strong sales of its drug Kimmtrak in the U.S. and internationally. The company is also advancing its pipeline, including phase III studies for Kimmtrak and brenetafusp, a lead ImmTAC candidate.
2026-08-07 12:27:00
Immunocore Holdings plc reported a Q2 2026 loss of 2 cents per share, wider than the Zacks Consensus Estimate. Despite the earnings miss, revenues increased 18.3% year-over-year to $115.9 million, surpassing estimates, driven by strong sales of its sole marketed drug, Kimmtrak. The company continues to advance its clinical programs, including several phase III studies for Kimmtrak and other ImmTAC candidates.
2026-08-07 04:14:00
Immunocore Holdings plc announced strong financial results for the second quarter and first half of 2026, driven by KIMMTRAK sales. The company reported $115.9 million in Q2 net revenues for KIMMTRAK, an 18% year-over-year increase, and highlighted positive five-year overall survival data for the drug in metastatic uveal melanoma. Immunocore also provided updates on its clinical pipeline, including progress in Phase 3 trials for advanced cutaneous melanoma and the development of new ImmTAC, ImmTAV, and ImmTAAI candidates for various diseases.
2026-08-07 02:11:00
Immunocore Holdings plc reported a significant Q2 2026 revenue increase to US$115.93 million and a narrower net loss, while the first half of 2026 saw US$222.60 million in revenue and US$12.16 million in net income, marking a shift to profitability compared to the prior year. This financial improvement, particularly the first-half profitability despite a small Q2 loss, is expected to positively influence investor perception and the company's investment narrative. The company's future hinges on its ImmTAC platform and KIMMTRAK franchise, with potential for further growth through late-stage melanoma trials, although pricing pressure in Europe remains a risk.
